MONOCLONAL-ANTIBODY LOCALIZATION IN SUBCUTANEOUS AND INTRACRANIAL HUMAN GLIOMA XENOGRAFTS - PAIRED-LABEL AND IMAGING ANALYSIS

  • 1 January 1984
    • journal article
    • research article
    • Vol. 4  (3) , 133-140
Abstract
The murine antiglioma monoclonal antibody 81C6 has been shown to specifically localize in U-251 MG and D-54 MG human glioma s.c. and intracranial athymic mouse xenografts expressing the human glioma-mesenchymal extracellular matrix glycoprotein GMEN. In paired-label studies 81C6 reached peak levels of localization in s.c. and intracranial xenografts in 24-48 h and persisted there for an additional 5 to 7 days before declining. The percent localized 81C6 in U-251 MG s.c. xenografts was tumor size dependent ranging from 2% in 200-300 mg tumors to 15% in 1-g tumors. S.c. xenografts of U-251 MG were readily radioimaged from 1 up to 6 days following administration of 131I-81C6. The specificity of 81C6 localization has also been demonstrated by tissue autoradiography, elution of radiolabeled 81C6 from tumor xenografts, and in vivo inhibition of radiolabeled 81C6 localization by unlabeled 81C6. D-54 MG intracranial xenografts were permeable to 81C6 and control Ig but specific localization occurred only with 81C6. Radiolabeled 81C6 monoclonal antibody and U-251 MG and D-54 MG human glioma xenografts provide a useful operationally tumor specific monoclonal antibody tumor localization model for the examination of monoclonal antibody pharmacokinetics, radioimaging, radioimmunotherapy and combined modality therapy in intracranial human glioma xenografts.